Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (411-420 of 436) with videos related to

Pageof 44
Sort By:
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Biorxiv : the Preprint Server for Biology|July 1, 2024
A Multi-Omics Approach to Defining Target Organ Injury in Youth with Primary HypertensionKalyani Ananthamohan, Tammy M Brady, Mohammed Arif, et al.
Circulation|May 29, 2008
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery diseaseMark Y Chan, Mauricio G Cohen, Christopher K Dyke, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
Hypertension (Dallas, Tex. : 1979)|June 28, 2022
Association of Blood Pressure-Related Increase in Vascular Stiffness on Other Measures of Target Organ Damage in YouthJessica E Haley, Shalayna A Woodly, Stephen R Daniels, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
Archives of Internal Medicine|January 16, 2008
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapyGustavo B F Oliveira, Eric M Crespo, Richard C Becker, et al.
Hypertension (Dallas, Tex. : 1979)|May 3, 2021
Team Science: American Heart Association's Hypertension Strategically Focused Research Network ExperienceMark K Santillan, Richard C Becker, David A Calhoun, et al.
Pageof 44

Showing results (411-420 of 436) with videos related to

Sort By:
Pageof 44
European Heart Journal|August 24, 2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trialGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Biorxiv : the Preprint Server for Biology|July 1, 2024
A Multi-Omics Approach to Defining Target Organ Injury in Youth with Primary HypertensionKalyani Ananthamohan, Tammy M Brady, Mohammed Arif, et al.
Circulation|May 29, 2008
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery diseaseMark Y Chan, Mauricio G Cohen, Christopher K Dyke, et al.
Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.
Thrombosis and Haemostasis|January 10, 2014
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic SubstudyRobert F Storey, Jayaprakash Kotha, Susan S Smyth, et al.
Journal of the American College of Cardiology|December 10, 2013
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)Shaun G Goodman, Daniel M Wojdyla, Jonathan P Piccini, et al.
Hypertension (Dallas, Tex. : 1979)|June 28, 2022
Association of Blood Pressure-Related Increase in Vascular Stiffness on Other Measures of Target Organ Damage in YouthJessica E Haley, Shalayna A Woodly, Stephen R Daniels, et al.
The New England Journal of Medicine|November 17, 2009
Platelet inhibition with cangrelor in patients undergoing PCIRobert A Harrington, Gregg W Stone, Steven McNulty, et al.
Archives of Internal Medicine|January 16, 2008
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapyGustavo B F Oliveira, Eric M Crespo, Richard C Becker, et al.
Hypertension (Dallas, Tex. : 1979)|May 3, 2021
Team Science: American Heart Association's Hypertension Strategically Focused Research Network ExperienceMark K Santillan, Richard C Becker, David A Calhoun, et al.
Pageof 44